Nabriva Therapeutics plc

Stock Exchange: XNAS Ticker: NBRV HQ: Dublin, Ireland Employees: 66 Signatory to Davos Decl: Yes Signatory to Industry Roadmap: No
Performance by research area
How Nabriva Therapeutics plc was evaluated
1 2.1 2.2 2.3 3 4
R&D A
1 2 3
M&P B
1 2 3 4 5 6 7
AA&S C
Applicable indicator Not applicable

Performance

Nabriva is a biopharmaceutical company, selected for having a pipeline that targets priority pathogens. It was evaluated in the area of Research & Development only. Nabriva has invested USD 48 million in antibiotic drug development in 2016. The company performs well compared to other biopharmaceutical companies in scope. Nabriva’s R&D pipeline consists of five projects, all of which target priority pathogens, including one novel antibiotic candidate. The company does not provide evidence of engaging in public-private partnerships and agreements to develop and commercialise its candidate compounds. Nabriva has no access or stewardship provisions in place for its late-stage clinical antimicrobial candidates.

Operations

Nabriva is a biopharmaceutical company engaged in research and development of novel antibiotics to treat bacterial infections, with a focus on the pleuromutilin class of antibiotics. Pleuromutilins were discovered in the 1950s and have since been used systemically in animals and topically in humans. In 2006, Nabriva was incorporated as a spin-off from the Sandoz GmbH Antibiotics Research Institute in Austria. The company then became public in 2015. In 2017, it relocated its corporate headquarters to Ireland. Nabriva is currently developing lefamulin, a semi-synthetic compound that inhibits the synthesis of bacterial protein. Lefamulin has recently completed a Phase III trial evaluating its safety and efficacy in patients with CABP. Nabriva is a member of the BEAM alliance, a group of biopharmaceutical companies addressing the regulatory and commercial environments in Europe regarding R&D, approval and market viability of products combating antimicrobial resistance. Nabriva has no products on the market. In 2016, the company had USD 6.5 million worth of revenues from research premiums and grants.

Antimicrobial Portfolio

Nabriva does not have any products on the market.

Opportunities

Plan ahead for access and stewardship during R&D. Nabriva is developing one antibiotic candidate (lefamulin) in late-stage clinical development. Nabriva can ensure access and stewardship provisions are in place for lefamulin, e.g., through partnerships

A. Research & Development

Indicators scored on
  • 1
  • 2.1
  • 2.2
  • 2.3
  • 3
  • 4
Antimicrobial pipeline
5 projects, 5 target priority pathogens

A.2.1-2.2 Pipeline focused on pleuromutilin antibiotics. 

Biopharmaceutical companies in scope were selected based on their pipelines that target priority bacteria. Nabriva invested USD 48 million in antibiotic drug development in 2016. The company has five projects in its antimicrobial R&D pipeline, all targeting priority pathogens, including one topical formulation. Currently, Nabriva has one systemic pleuromutilin antibiotic (lefamulin) in Phase III clinical trials to evaluate the safety and efficacy of intravenous to oral lefamulin in patients with CABP. Nabriva intends to develop lefamulin for additional indications, including for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and for paediatric use. Lefamulin is seen by WHO as a new innovative antibiotic, as this is the first pleuromutilin for systemic use in humans. Additionally, Nabriva is developing a pleuromutilin in topical form (BC7013) for the treatment of uncomplicated skin and skin structure infections (uSSSI). The company also owns a pleuromutilin discovery platform.

A.3 No public-private partnerships reported. 

Nabriva conducts R&D in-house and/or with private- sector partners. It does not participate in public-private partnerships, or in partnerships with non-profit organisations, for antimicrobial R&D.

A.4 No information on access or stewardship provisions. 

Nabriva reports no information on access or stewardship provisions for its antibiotic candidate in late-stage development. It has signed the Davos Declaration, which includes a general commitment to ensuring access to antimicrobial medicines and vaccines, and to support the appropriate and responsible use of these products.

Pipeline targeting priority pathogens

Enlarge

B. Manufacturing & Production

As a biopharmaceutical company with no products on the market, Nabriva was not eligible for this Research Area.

C. Appropriate Access & Stewardship

As a biopharmaceutical company with no products on the market, Nabriva was not eligible for this Research Area.



Got a question?

Learn more

View our detailed overview of each company’s performance